All In Biotech

Drug Trial Radar · NCT01306929

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).

Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

134

Actual

Start

Mar 24, 2011

Primary completion

Jan 5, 2018

Study completion Jan 5, 2018

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
First posted
Mar 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.

Conditions

  • Huntington Disease

Interventions

  • pridopidineDrug

    45mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With at Least One Adverse EventTime frame: From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.